Columbia Partners L L C Investment Management grew its position in shares of TESARO, Inc. (NASDAQ:TSRO) by 27.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,269 shares of the biopharmaceutical company’s stock after acquiring an additional 3,096 shares during the quarter. Columbia Partners L L C Investment Management’s holdings in TESARO were worth $1,995,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its holdings in shares of TESARO by 2.1% during the first quarter. Teacher Retirement System of Texas now owns 2,945 shares of the biopharmaceutical company’s stock valued at $453,000 after acquiring an additional 60 shares during the period. Profund Advisors LLC boosted its holdings in shares of TESARO by 3.8% during the first quarter. Profund Advisors LLC now owns 2,562 shares of the biopharmaceutical company’s stock valued at $394,000 after acquiring an additional 93 shares during the period. Stephens Inc. AR boosted its holdings in shares of TESARO by 6.5% during the second quarter. Stephens Inc. AR now owns 1,874 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 115 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of TESARO by 0.9% during the first quarter. State Board of Administration of Florida Retirement System now owns 16,740 shares of the biopharmaceutical company’s stock valued at $2,576,000 after acquiring an additional 150 shares during the period. Finally, Aperio Group LLC boosted its holdings in shares of TESARO by 4.5% during the second quarter. Aperio Group LLC now owns 3,658 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 156 shares during the period.

Shares of TESARO, Inc. (TSRO) traded down 1.440% during midday trading on Tuesday, reaching $116.735. 157,939 shares of the company’s stock traded hands. The firm’s market capitalization is $6.32 billion. TESARO, Inc. has a 52-week low of $96.52 and a 52-week high of $192.94. The stock’s 50 day moving average price is $121.29 and its 200 day moving average price is $139.39.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. TESARO’s revenue was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.28) EPS. On average, equities research analysts anticipate that TESARO, Inc. will post ($8.67) EPS for the current fiscal year.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/19/columbia-partners-l-l-c-investment-management-has-2-million-stake-in-tesaro-inc-tsro.html.

Several brokerages have recently issued reports on TSRO. BidaskClub downgraded shares of TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Robert W. Baird reissued a “neutral” rating on shares of TESARO in a report on Tuesday, June 6th. Bank of America Corporation reissued a “buy” rating and set a $154.00 price target on shares of TESARO in a report on Tuesday, June 20th. Wedbush reissued an “outperform” rating and set a $160.00 price target on shares of TESARO in a report on Monday, September 11th. Finally, ValuEngine downgraded shares of TESARO from a “hold” rating to a “sell” rating in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $171.42.

In related news, VP Edward C. English sold 10,862 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the transaction, the vice president now owns 6,258 shares in the company, valued at $844,329.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,100 shares of company stock worth $3,387,465. 34.60% of the stock is owned by company insiders.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.